Drug Enforcement Administration
The OIG is examining the DEA’s use of administrative subpoenas to obtain broad collections of data or information. The review will address the legal authority for the acquisition or use of these data collections; the existence and effectiveness of any policies and procedural safeguards established with respect to the collection, use, and retention of the data; the creation, dissemination, and usefulness of any products generated from the data; and the use of “parallel construction” or other techniques to protect the confidentiality of these programs.
Audit of the Drug Enforcement Administration's Community-Based Efforts to Combat the Opioid Crisis
The OIG is conducting an audit of the DEA's community-based efforts to combat the opioid crisis. The preliminary objectives are to: (1) examine the DEA’s pilot city-selection methodology, (2) assess the DEA’s integration of a performance measurement strategy to enhance its community-based efforts, (3) evaluate the DEA’s collaboration with other agencies in combatting the opioid crisis, and (4) assess the DEA’s efforts to sustain progress in the communities it assists.
DEA’s Controls over Weapons, Munitions, and Explosives
The OIG is auditing DEA’s controls over weapons, munitions, and explosives, including firearms, Tasers, ammunition, less-lethal munitions, and diversionary devices. The preliminary objectives are to evaluate: (1) DEA’s controls over weapons, munitions, and explosives; (2) DEA’s compliance with policies governing weapons, munitions, and explosives; and (3) the accuracy of DEA’s weapons, munitions, and explosives inventories.
DEA's Income-Generating Undercover Operations
The OIG is conducting an audit of the DEA's income-generating undercover operations. The preliminary objectives are to evaluate the management and oversight of DEA’s income-generating operations with respect to: (1) the initiation and classification of these operations, (2) the controls over and use of funds during operations, and (3) the disposal of proceeds at the conclusion of these operations.
DEA's Prescription Drug Take Back Activities
The OIG is auditing DEA’s prescription drug take back activities. The preliminary objective is to evaluate the DEA’s policies, procedures, and practices for the collection, custody, and disposal of prescription drugs.
DOJ's Compliance with the Federal Funding Accountability and Transparency Act of 2006, as amended by the DATA Act of 2014
The OIG is examining DOJ's compliance with reporting requirements under the Federal Funding Accountability and Transparency Act, as amended by the DATA Act. Through memorandum M-15-12, Increasing Transparency of Federal Spending by Making Federal Spending Data Accessible, Searchable, and Reliable, the Office of Management and Budget provided guidance to federal agencies on the requirements that agencies must employ pursuant to the DATA Act. The OIG will review a statistically valid sampling of the fiscal year 2019 spending data submitted, and submit to Congress and make publicly available a report assessing the completeness, timeliness, quality, and accuracy of the data sampled.
DOJ’s Use of Immigration Sponsorship Programs
The OIG is conducting an audit of DOJ’s use of immigration sponsorship programs. The objectives are to assess: (1) the oversight of DOJ components’ foreign national sponsorship activities, and (2) the coordination within the DOJ components and with DHS to ensure the accuracy of information regarding foreign national sponsorships.
Review of the Department of Justice’s Preparedness to Respond to Critical Incidents Under Emergency Support Function 13
The OIG is reviewing the Department’s ability to meet its responsibilities under Emergency Support Function 13 (ESF-13) and to execute ESF-13 activities in response to natural and manmade disasters. OIG will assess Departmental policies and guidance; planning, preparation, training, and execution processes; and coordination among DOJ law enforcement components and non-DOJ support agencies in support of an ESF-13 activation.
Review of the Drug Enforcement Administration’s Opioid Enforcement Efforts
The OIG is assessing whether DEA’s regulatory activities and enforcement efforts effectively prevent the diversion of controlled substances, particularly opioids, to unauthorized users. Specifically, this review will examine (1) DEA’s enforcement regulations, policies, and procedures; (2) DEA’s use of enforcement actions involving manufacturers, distributors, physicians, and pharmacists who violate these policies and procedures; and (3) DEA’s coordination with state and local partners to combat the opioid epidemic.
To detect and deter waste, fraud, abuse, and misconduct in DOJ programs and personnel, and to promote economy and efficiency in those programs.